The opioid crisis suggests a painful financial future for some drug makers

Between falling prices for many of the medicines and fast-growing litigation, a few of these companies have only modest flexibility to cope with these mounting risks, according to a new analysis by Moody’s Investor Service. And the drug maker most likely to be impacted is Endo International (ENDP).

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!